TRX-4 (TolerRx Inc)
Brown, W.M.
Idrugs the Investigational Drugs Journal 9(4): 283-291
2006
ISSN/ISBN: 1369-7056 PMID: 16596483 Document Number: 604117
TolerRx Inc, under license from BTG plc, is developing TRX-4, an anti-CD3 humanized monoclonal antibody for the potential treatment of type 1 diabetes and psoriasis. Phase II trials of the therapeutic antibody in type 1 diabetes have been completed and the company is planning a pivotal phase III trial for this indication. TolerRx is also enrolling psoriasis patients in a phase Ib clinical study of TRX-4. TRX-4 has been awarded Orphan Drug status for recent-onset type 1 diabetes.